Loading...
MSN Laboratories Private Limited — Exemestane Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #4 for Exemestane · $1.7M export value · DGFT Verified
MSN Laboratories Private Limited is the #4 Indian exporter of Exemestane with $1.7M in export value and 34 verified shipments. MSN Laboratories Private Limited holds a 11.7% market share in Exemestane exports across 1 countries. The company exports 32 pharmaceutical products worth $252.1M across 15 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $4.2M | 83 | 37.3% |
| NETHERLANDS | $1.7M | 80 | 15.2% |
| UNITED KINGDOM | $1.4M | 27 | 12.1% |
| GERMANY | $882.2K | 25 | 7.9% |
| BRAZIL | $800.0K | 16 | 7.2% |
| MEXICO | $446.1K | 12 | 4.0% |
| HUNGARY | $400.0K | 8 | 3.6% |
| GREECE | $242.9K | 9 | 2.2% |
| AUSTRALIA | $224.2K | 13 | 2.0% |
| VENEZUELA | $215.1K | 7 | 1.9% |
India exports Exemestane to 57 countries. The top destination is UNITED STATES (37.3%), followed by NETHERLANDS and UNITED KINGDOM.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CARDINAL HEALTH | UNITED STATES | $800.0K | 16 |
| BROCACEF NL HUB | NETHERLANDS | $699.9K | 20 |
| FIEGE HEALTHCARE LOGISTICS GMBH | GERMANY | $604.5K | 19 |
| AUROBINDO PHARMA USA., INC, | UNITED STATES | $450.0K | 9 |
| CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $450.0K | 9 |
India exported $10.9M worth of Exemestane through 1,533 shipments from 87 suppliers to 57 countries, serving 196 buyers globally. MSN Laboratories Private Limited contributes $1.7M to this total, accounting for 11.7% of India's Exemestane exports.
MSN Laboratories Private Limited's average Exemestane shipment value is $50.0K per consignment, based on 34 shipments totaling $1.7M.
MSN Laboratories Private Limited ranks #4 among 87 Indian Exemestane exporters with a 11.7% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($4.5M), MSN LABORATORIES PRIVATE LIMITED ($1.7M), EUGIA PHARMA SPECIALITIES LIMITED ($1.4M). MSN Laboratories Private Limited processed 34 shipments to 1 destination countries.
What MSN Laboratories Private Limited must comply with to export Exemestane to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED | $4.5M | 260 | 21 | $17.3K |
| 4 | MSN LABORATORIES PRIVATE LIMITED ★ | $1.7M | 34 | 1 | $50.0K |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED | $1.4M | 27 | 1 | $50.0K |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $900.0K | 18 |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 314 | 20.5% |
| DELHI AIR CARGO ACC (INDEL4) | 273 | 17.8% |
| SAHAR AIR | 256 | 16.7% |
| DELHI AIR | 128 | 8.3% |
| Bombay Air Cargo | 62 | 4.0% |
| MUNDRA SEA (INMUN1) | 52 | 3.4% |
| MUNDRA SEA | 51 | 3.3% |
| AHEMDABAD AIR ACC (INAMD4) | 50 | 3.3% |
MSN Laboratories Private Limited also exports these advanced oncology products. Each links to the detailed product page.
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like MSN Laboratories. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major shipping lines to alter routes. This has resulted in extended transit times by 10–20 days and a 40–50% increase in freight rates on key India–Europe routes, impacting the timely delivery of pharmaceutical products. (livemint.com)
Conversely, the ongoing US-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, potentially benefiting Indian exporters. However, the imposition of tariffs on Indian pharmaceutical products poses a risk to export volumes, as higher tariffs can lead to increased costs and reduced competitiveness in the US market. (orfonline.org)
In the European Union, compliance with the Falsified Medicines Directive (FMD) requires stringent serialization and traceability measures. For companies like MSN Laboratories, adhering to these regulations is crucial to maintain market access and ensure the integrity of their supply chain.
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA), World Health Organization (WHO), and European Union Good Manufacturing Practice (EU GMP) guidelines set rigorous quality benchmarks. Any lapses can lead to import bans, product recalls, and reputational damage.
MSN Laboratories' recent legal challenges, such as the patent litigation with Exelixis, Inc., highlight the importance of robust regulatory and intellectual property strategies. Ensuring compliance with evolving quality requirements and proactively addressing regulatory challenges are essential for sustaining export growth and market credibility.
MSN Laboratories Private Limited exports 32 products worth $252.1M. Beyond Exemestane, top products include Atorvastatin, Rosuvastatin, Ras, Oseltamivir, Calcium. View the complete MSN Laboratories Private Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Exemestane — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for MSN Laboratories Private Limited's Exemestane exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
MSN Laboratories Private Limited
Full Company Profile →
32 products · $252.1M total trade · 15 categories
| XXDUSXXHARXXCEUXXCALXXUSAXXNC |
| UNITED STATES |
| $300.0K |
| 6 |
| ZYDUS PHARMACEUTICALS USA INC | UNITED STATES | $250.0K | 5 |
| M P L | UNITED KINGDOM | $200.0K | 4 |
| AUROBINDO PHARMA USA INC | UNITED STATES | $150.0K | 3 |
| AUROBINDO PHARMA USA., INC | UNITED STATES | $150.0K | 3 |
India's Exemestane is purchased by 196 buyers worldwide. The top buyer is CARDINAL HEALTH (UNITED STATES), followed by BROCACEF NL HUB and FIEGE HEALTHCARE LOGISTICS GMBH.
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 4 |
| $50.0K |
MSN Laboratories Private Limited ranks #4 among 87 Indian Exemestane exporters. Average shipment value of $50.0K compared to the market average of $124.9K. The closest competitors by value are INTAS PHARMACEUTICALS LIMITED and EUGIA PHARMA SPECIALITIES LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 57+ countries, 196+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for MSN Laboratories Private Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Exemestane. For current shipment-level data, contact TransData Nexus.